ProfileGDS5678 / 1419499_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 81% 88% 87% 90% 85% 88% 94% 94% 87% 81% 87% 88% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.2649485
GSM967853U87-EV human glioblastoma xenograft - Control 25.9055981
GSM967854U87-EV human glioblastoma xenograft - Control 36.833588
GSM967855U87-EV human glioblastoma xenograft - Control 46.923587
GSM967856U87-EV human glioblastoma xenograft - Control 57.3879890
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.2064785
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.7391188
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.0371994
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.9903694
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.785587
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.7527781
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.7086287
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.8284188
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.6693687